Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)

Phase 4
Recruiting
Conditions
Interventions
First Posted Date
2019-09-12
Last Posted Date
2022-03-16
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
440
Registration Number
NCT04088513
Locations
🇨🇳

Longyan First Hospital, Longyan, Fujian, China

🇨🇳

The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China

🇨🇳

The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

and more 16 locations

Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2019-09-06
Last Posted Date
2024-11-05
Lead Sponsor
Children's Hospital of Fudan University
Target Recruit Count
3200
Registration Number
NCT04078568
Locations
🇨🇳

Bengbu First People's Hopital, Bengbu, Anhui, China

🇨🇳

Anhui Children's Hospital, Hefei, Anhui, China

🇨🇳

Children's Hospital, Capital Institute of Pediatrics, Beijing, Beijing, China

and more 33 locations

Low Doses of Aspirin in the Prevention of Preeclampsia

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2019-08-28
Last Posted Date
2024-10-31
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
400
Registration Number
NCT04070573
Locations
🇺🇸

New York Presbyterian - Weill Cornell, New York, New York, United States

🇺🇸

New York Presbyterian Queens, New York, New York, United States

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

First Posted Date
2019-08-16
Last Posted Date
2021-07-21
Lead Sponsor
Boston Scientific Corporation
Registration Number
NCT04059536
Locations
🇺🇸

Cardiovascular Research of North Florida LLC, Gainesville, Florida, United States

🇺🇸

St. Mary Medical Center, Inc., Hobart, Indiana, United States

🇺🇸

Ascension St. John Hospital, Detroit, Michigan, United States

and more 7 locations

Asprin Dosing Estimator in Healthy Adults

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-07-31
Last Posted Date
2022-03-11
Lead Sponsor
University of Utah
Target Recruit Count
57
Registration Number
NCT04040465
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer

First Posted Date
2019-07-30
Last Posted Date
2021-11-22
Lead Sponsor
University of Virginia
Registration Number
NCT04038489
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

Risk Stratification Procedure for Thromboembolism Prophylaxis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2019-07-24
Last Posted Date
2020-02-25
Lead Sponsor
Ministry of Health, Saudi Arabia
Target Recruit Count
242
Registration Number
NCT04031859
Locations
🇸🇦

Prince Sultan Medical Military City, Riyadh, Saudi Arabia

The Safety and Efficacy of RIC on Adult Moyamoya Disease

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2019-07-09
Last Posted Date
2021-03-12
Lead Sponsor
Capital Medical University
Target Recruit Count
30
Registration Number
NCT04012268
Locations
🇨🇳

Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

First Posted Date
2019-07-05
Last Posted Date
2023-04-26
Lead Sponsor
University of Florida
Target Recruit Count
90
Registration Number
NCT04006288
Locations
🇺🇸

University of Florida, Jacksonville, Florida, United States

Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex

Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-07-05
Last Posted Date
2019-07-05
Lead Sponsor
PLx Pharma
Target Recruit Count
32
Registration Number
NCT04008979
© Copyright 2024. All Rights Reserved by MedPath